EFFICACY AND SAFETY OF TIBOLONE IN POSTMENOPAUSAL WOMEN

替勃龙对绝经后女性的疗效和安全性

• 批准号: 3743867
• 负责人: JOSEPH MORTOLA
• 金额: --
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3743867
• 关键词: chemoprevention; disease /disorder prevention /control; dosage; drug quality /standard; drug screening /evaluation; female; human subject; human therapy evaluation; osteoporosis; postmenopause; skeletal disorder chemotherapy

To determine the minimum effective dose of Tibolone for prevention of menopausal osteoporosis and to demonstrate the efficacy, safety and acceptability of the medication at the therapeutic dose for this indication.

确定替勃龙预防糖尿病的最低有效剂量 绝经期骨质疏松症，并证明其疗效、安全性和 治疗剂量的药物对此的可接受性 适应症